Artio Medical, a medical device company developing innovative products for the peripheral vascular and neurovascular markets, has closed an additional $8.8 million in Series A financing, bringing the total capital raised to date to more than $20 million. The additional funds will help Artio obtain 510(k) marketing clearance from the FDA to market the Solus Gold embolisation device in the USA.
Nathaniel Hagedorn, founder and CEO of Northpoint Development, comments: “Artio is developing a strong portfolio of disruptive, next-generation peripheral vascular and neurovascular embolisation products, and we were thrilled to help lead the latest round of funding. I have been incredibly fortunate to have so many people help me build my business and am happy to ‘pay it forward’ to a fellow entrepreneur with a clear vision and accomplished team.”
F Nicholas Franano, president and CEO of Artio, says: “We appreciate the strong support from our new and existing investors. Our team is looking forward to making our innovative products available to physicians and patients.”